Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Infinity Pharmaceuticals Inc. (INFI)

INFIQ

PR Newswire

NEW YORK, June 15, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Infinity Pharmaceuticals Inc. ("Infinity" or "the Company") (NASDAQ: INFI). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. 

This investigation concerns whether Infinity and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act"). 

On June 14, 2016, premarket, Infinity revealed that they would be reducing its workforce by 21% following poor drug-study results.  The Phase 2 study of its treatment for non-Hodgkin lymphoma met its primary endpoint of overall response rate, but Infinity said it was hoping to provide a larger clinical benefit.  

Following this news, Infinity stock dropped $3.05 per share, or roughly 69%, to close at $1.36 per share on June 14, 2016.

If you are aware of any facts relating to this investigation, or purchased shares of Infinity, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!infi/ljhl9. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-infinity-pharmaceuticals-inc-infi-300285259.html

SOURCE Bronstein, Gewirtz & Grossman, LLC



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today